First-line treatment duration may be a clinically useful predictor for 177Lu-DOTATATE retreatment patient selection, ...
According to data from the SwissNET registry of patients with GI-NETS, response to [177Lu]Lu-edotreotide is not influenced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results